Erik Rasmussen

6.7k total citations · 3 hit papers
107 papers, 4.6k citations indexed

About

Erik Rasmussen is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Erik Rasmussen has authored 107 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 35 papers in Molecular Biology and 28 papers in Hematology. Recurrent topics in Erik Rasmussen's work include Multiple Myeloma Research and Treatments (23 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Erik Rasmussen is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), CAR-T cell therapy research (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Erik Rasmussen collaborates with scholars based in United States, Australia and Germany. Erik Rasmussen's co-authors include Bart Barlogie, John D. Shaughnessy, Ronald C. Walker, Fenghuang Zhan, Erming Tian, Yupo Ma, Richard D. Todd, Rosalind J. Neuman, Andrew C. Heath and Guido Tricot and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Erik Rasmussen

102 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

2003 1.1k citations Erik Rasmussen, Bart Barlogie et al. New England Journal of Medicine profile →
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. New England Journal of Medicine profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Erik Rasmussen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Rasmussen United States	31	2.2k	2.0k	1.4k	552	539	107	4.6k
Antonio Giovanni Solimando Italy	38	1.3k 0.6×	1.1k 0.6×	689 0.5×	473 0.9×	500 0.9×	129	3.1k
James M. Foran United States	37	1.2k 0.5×	2.0k 1.0×	2.0k 1.4×	427 0.8×	605 1.1×	243	5.4k
Jordi Bruna Spain	40	752 0.3×	2.4k 1.2×	734 0.5×	1.2k 2.2×	104 0.2×	151	4.8k
Anthony A. Amato United States	48	3.4k 1.6×	738 0.4×	681 0.5×	225 0.4×	1.2k 2.2×	148	8.7k
Lidia Larizza Italy	43	3.7k 1.7×	530 0.3×	578 0.4×	496 0.9×	577 1.1×	271	6.3k
Paolo A. Muraro United Kingdom	41	803 0.4×	1.4k 0.7×	917 0.7×	229 0.4×	1.9k 3.5×	128	5.9k
Lucienne Michaux Belgium	38	1.3k 0.6×	1.1k 0.5×	1.6k 1.1×	347 0.6×	982 1.8×	184	4.5k
Martin Zenker Germany	40	4.0k 1.8×	1.1k 0.5×	217 0.2×	301 0.5×	1.3k 2.5×	227	6.3k
Ulrich Jaeger Austria	41	1.8k 0.8×	2.2k 1.1×	1.4k 1.0×	561 1.0×	1.4k 2.6×	210	7.0k
Peter J. Rosen United States	29	870 0.4×	1.1k 0.5×	509 0.4×	740 1.3×	178 0.3×	100	2.9k

Countries citing papers authored by Erik Rasmussen

Since Specialization

Citations

This map shows the geographic impact of Erik Rasmussen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Rasmussen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Rasmussen more than expected).

Fields of papers citing papers by Erik Rasmussen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Rasmussen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Rasmussen. The network helps show where Erik Rasmussen may publish in the future.

Co-authorship network of co-authors of Erik Rasmussen

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Rasmussen. A scholar is included among the top collaborators of Erik Rasmussen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Rasmussen. Erik Rasmussen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jensen, Tue Secher, et al.. (2022). Appropriateness of referrals from primary care for lumbar MRI. Chiropractic & Manual Therapies. 30(1). 9–9. 3 indexed citations

Li, Yanxia, Nelusha Amaladas, Jason R. Manro, et al.. (2022). Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE. 17(7). e0268244–e0268244. 11 indexed citations

Herbst, Roy S., Johanna C. Bendell, Edward Arrowsmith, et al.. (2020). Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology. 16(2). 289–298. 44 indexed citations

Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1125–S1126. 3 indexed citations

Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology. 14(10). S208–S208. 30 indexed citations

Rosenthal, Mark, Richard Curry, David A. Reardon, et al.. (2019). Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemotherapy and Pharmacology. 84(2). 327–336. 45 indexed citations

Tran, Ben, Richard D. Carvajal, Aurélien Marabelle, et al.. (2018). Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 6(1). 93–93. 62 indexed citations

Carducci, Michael A., Montaser Shaheen, Ben Markman, et al.. (2018). A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. 36(6). 1060–1071. 33 indexed citations

Papadopoulos, Kyriakos P., Lainie P. Martin, Anthony J. Olszanski, et al.. (2017). First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 23(19). 5703–5710. 157 indexed citations

10.

Dowlati, Afshin, Gordana Vlahovic, Ronald B. Natale, et al.. (2016). A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(18). 4574–4584. 16 indexed citations

11.

Padhi, Desmond, Celestia S. Higano, Neal D. Shore, et al.. (2014). Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Clinical Endocrinology & Metabolism. 99(10). E1967–E1975. 63 indexed citations

12.

Lü, Jianfeng, Erik Rasmussen, Beth Y. Karlan, et al.. (2011). Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology. 69(5). 1135–1144. 34 indexed citations

13.

Mikaelian, Igor, Andreas Buneß, Erik Rasmussen, et al.. (2010). Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs. Toxicological Sciences. 117(1). 144–151. 43 indexed citations

14.

Wallace, Daniel J., Michael H. Weisman, Mariko Ishimori, et al.. (2009). Sample stability and variability of B‐cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus. Cytometry Part B Clinical Cytometry. 78B(1). 49–58. 10 indexed citations

15.

Winnerkvist, Anders, Ulf Lockowandt, Erik Rasmussen, & Kjell Rådegran. (2006). A Prospective Study of Medically Treated Acute Type B Aortic Dissection. Journal of Vascular Surgery. 44(4). 907–907. 1 indexed citations

16.

Barlogie, Bart, Guido Tricot, Elias Anaissie, et al.. (2006). Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine. 354(10). 1021–1030. 532 indexed citations breakdown →

17.

Rasmussen, Erik, Rosalind J. Neuman, Andrew C. Heath, et al.. (2002). Replication of the latent class structure of Attention‐Deficit/Hyperactivity Disorder (ADHD) subtypes in a sample of Australian twins. Journal of Child Psychology and Psychiatry. 43(8). 1018–1028. 95 indexed citations

18.

Todd, Richard D., Erik Rasmussen, Rosalind J. Neuman, et al.. (2001). Familiality and Heritability of Subtypes of Attention Deficit Hyperactivity Disorder in a Population Sample of Adolescent Female Twins. American Journal of Psychiatry. 158(11). 1891–1898. 141 indexed citations

19.

Rohde, Luís Augusto, Genário Alves Barbosa, Guilherme V. Polanczyk, et al.. (2001). Factor and Latent Class Analysis of DSM-IV ADHD Symptoms in a School Sample of Brazilian Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. 40(6). 711–718. 68 indexed citations

20.

Kanes, Stephen, Katherine M. Dains, Laura Cipp, et al.. (1996). Mapping the genes for haloperidol-induced catalepsy.. Journal of Pharmacology and Experimental Therapeutics. 277(2). 1016–1025. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact